Inozyme Pharma
(NASDAQ) INZY
Inozyme Pharma Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$106.72M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
INZY News
INZY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Inozyme Pharma
Industry
Biotechnology
Sector
Health CareEmployees
67
CEO
Doug Treco Treco, PhD
Website
www.inozyme.comHeadquarters
Boston, MA 02210, US
INZY Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-1%
Return on Capital
-2%
Return on Assets
-84%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$104.03M
EBITDA
$104.03M
Operating Cash Flow
$91.91M
Capital Expenditure
$62.00K
Free Cash Flow
$91.97M
Cash & ST Invst.
$113.09M
Total Debt
$46.87M
Inozyme Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
67
N/A
Net Income
$28.04M
-20.1%
EBITDA
$26.46M
-21.1%
Quarterly Fundamentals
Net Cash
$37.82M
-68.4%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$20.59M
-55.0%
Short Term Debt
$26.37M
+2723.2%
Return on Assets
-83.73%
N/A
Return on Invested Capital
-1.52%
N/A
Free Cash Flow
$29.15M
-18.7%
Operating Cash Flow
$29.15M
-18.8%